ASCO 2023 | Learning lessons from previous trials of ADCs in colorectal cancer

Jennifer Rachel Eads, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, comments on challenges in developing antibody-drug conjugates (ADCs) for patients with colorectal cancer (CRC). The complexity of ADCs, which consist of a monoclonal antibody chemically linked to a cytotoxic drug, has hampered efforts in their clinical implantation in CRC. Linker degradation and payloads unsuitable for colorectal cancer tumors have also contributed to multiple trials with negative results. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.